RNXT NASDAQ
RenovoRx, Inc.
1W: -4.8%
1M: -37.3%
3M: +66.7%
YTD: +89.2%
1Y: +17.9%
3Y: +21.5%
5Y: -77.5%
$1.58
+0.03 (+1.94%)
Weekly Expected Move ±12.0%
$1
$1
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$71.2M
52W Range0.7006-2.59
Volume269,360
Avg Volume614,824
Beta0.99
Dividend—
Analyst Ratings
Company Info
CEOShaun R. Bagai
Employees17
SectorHealthcare
IndustryBiotechnology
IPO Date2021-08-26
Websiterenovorx.com
4546 El Camino Real
Mountain View, CA 94040
US
Mountain View, CA 94040
US
650 284 4433
About RenovoRx, Inc.
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Latest News
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
RenovoRx, Inc. (NASDAQ:RNXT) Stock Short Interest Jumps 55.7%
These low-priced stocks are flashing overbought signals
The best Quant-rated stocks trading below $10 right now
RenovoRx FY2026 EPS Raised by Ascendiant Capital Markets
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Macfarlane K. Angela | A-Award | 55,924 | $1.55 | 2026-10-01 |
| Spiegel Robert J. | A-Award | 55,924 | $1.55 | 2026-10-01 |
| RYAN UNA S | A-Award | 55,924 | $1.55 | 2026-10-01 |
| Marton Laurence | A-Award | 55,924 | $1.55 | 2026-10-01 |
| VOLL MARK | A-Award | 80,000 | — | 2026-09-10 |